Impact of Daily Glucose Fluctuation on Vessel Healing after 2nd Generation Drug-eluting Stent Implantation Assessed by Continuous Glucose Monitoring and Optical Coherence Tomography

Impact of Daily Glucose Fluctuation on Vessel Healing after 2nd Generation Drug-eluting Stent Implantation Assessed by Continuous Glucose Monitoring and Optical Coherence Tomography - Impact of Daily Glucose Fluctuation on Vessel Healing after 2nd Generation Drug-eluting Stent Implantation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019704

Enrollment

Registered

2015-11-10

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stable angina pectoris

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients whose glucose fluctuation was assessed by continuous glucose monitoring before percutaneous coronary intervention (PCI) 2)patients treated with everolimus-eluting stent at PCI 3)LDL-chol < 100mg/dl in patients without statin. LDL-chol < 120mg/dl in patients with statin. 4)patients between 20 and 80 years old 5)written consent for participation in the study

Exclusion criteria

Exclusion criteria: Patients meeting one of the following conditions will be excluded: 1) treated with other kind of stent 2) unsuitable anatomy for OCT analysis in stented segment 3) severe renal dysfunction 4) any change of medical interventions for the control of diabetes, lipids, and hypertension during this study 5) judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
Association between glucose variability and neointimal proliferation nine (six to twelve) months after stenting assessed continuous glucose monitoring (CGM) and coronary imaging device (optical coherence tomography; OCT)	—

Secondary

Measure	Time frame
Major cardiovascular adverse events (target lesion revascularization, myocardial infarction and cardiac death) at nine (six to twelve) months after percutaneous coronary intervention.	—

Countries

Japan

Contacts

Public ContactMasaru Kuroda

Kobe University Graduate School of Medicine Division of Cardiovascular Medicine

kuroro19800115@hotmail.com078-382-5846

Outcome results